Vytorin fails test

Donald Caminiti

Contributor

0 CommentsPrint ArticleSubscribe

In a recent SEAS study, it was determined that the cholesterol reducing drug, Vytorin, did not prevent worsening of heart valve disease or lower the need for valve surgery.

Preliminary results showed that Vytorin, a combination of Zocor and Zetia, was no better than placebos at lowering the risk of major cardiovascular events, including heart attack, stroke, heart surgery and death in patients with aortic stenosis, although it did cut cholesterol levels about 60 percent.

Vytorin did however cut cholesterol levels about 60 percent